feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouIndiaIndia
You
bookmarksYour BookmarkshashtagYour Topics
Trending
trending

CAG: issues with GST payment

trending

Reddit post aided FBI capture

trending

Delhi fog disrupts flights

trending

Sreenivasan passes away at 69

trending

India wins T20 series

trending

Suryakumar, Gill's form a concern

trending

AICTE IDE Bootcamp kicks off

trending

Duckett out, England struggle

trending

Lyon spins out Harry Brook

Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2025 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / Africa Launches HIV Injectable: Twice Yearly Protection

Africa Launches HIV Injectable: Twice Yearly Protection

1 Dec

•

Summary

  • New HIV injection offers over 99.9% protection, taken twice yearly.
  • South Africa, Eswatini, and Zambia are first to administer the drug.
  • US program provides millions of doses to high-burden countries.
Africa Launches HIV Injectable: Twice Yearly Protection

Africa is pioneering the rollout of lenacapavir, a groundbreaking injectable for HIV prevention administered only twice annually. South Africa, Eswatini, and Zambia commenced public administration of the drug, which has demonstrated over 99.9% efficacy in reducing HIV risk, akin to a potent vaccine. This launch signifies a major stride in regions grappling with the world's highest HIV prevalence.

The injectable's initial deployment is supported by initiatives like Unitaid and a US program that aims to provide two million doses to high-burden nations over three years. While South Africa is funding its own rollout, other countries like Eswatini and Zambia have received initial doses through the US initiative, bolstering national HIV response efforts and offering renewed hope.

Despite these advancements, concerns about drug pricing and accessibility persist, with critics highlighting the market price as prohibitive for many. The move to make generic versions available by 2027 offers future hope for broader access, as progress against HIV faces new challenges amid funding shifts.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
The new HIV prevention injection was launched in South Africa on Monday.
Lenacapavir has been shown to reduce the risk of HIV transmission by more than 99.9 percent.
Lenacapavir is administered via injection twice a year.

Read more news on

Healthside-arrowSouth Africaside-arrow

You may also like

Falcons Fly Far: Amur Birds Reach Africa!

27 Nov • 128 reads

article image

Nissanka's 98 Powers Sri Lanka to Dominant Win

25 Nov • 137 reads

article image

Raza Shut Downs Asian Rankings Question

20 Nov • 142 reads

article image

India's Cashew Consumption to Double by 2045

15 Nov • 171 reads

article image

Malaria Fighters Unveil Promising New Treatments to Tackle Drug Resistance

13 Nov • 156 reads

article image